ClinicalTrials.gg
RecruitingNCT07851038VANTUSUpdated Oct 27, 2026

Focused Ultrasound for Behavioral Health

An interventional study of ATTN201 head-worn focused ultrasound in Depression, Anxiety and Obsessive Compulsive Disorder (OCD), sponsored by Attune Neurosciences Inc. Recruiting at 2 sites in United States. Open to participants aged 22 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Attune Neurosciences Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 27, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
22 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,715 studies in Depression with a site in United States — 579 open to participants now, 716 under way, 29 of them phase 3. Depression · United States.

Planned enrollment
559th of 3,322
300 · median 72
Started
2026
with 179 others
No phase
2,221 of 3,715
386 open now
Primary completion
2028-04
later than 504 of 714 live
Registered
3,674th of 3,715
by date

Among the 3,715 studies in Depression with a site in United States, this one is the 559th largest by planned enrollment of the 3,322 interventional ones that give a count, is one of 180 that started in 2026, is one of 2,221 with no phase, reaches primary completion later than 504 of the 714 other live ones, and was the 3,674th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

579 of the 3,715 studies in Depression with a site in United States are open now. Recruiting first, the newest first:

573 more — sign in →

All 579 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 22 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,715 studies in Depression with a site in United States, or all of them as a file.
02

Study summary

This is a double-blind, within-participant crossover, multi-site dose-finding study evaluating the safety, feasibility, and preliminary efficacy of repeated low-intensity focused ultrasound (LIFU) stimulation using the ATTN201 device across seven candidate deep-brain targets in adults with subsyndromal-to-moderate depression, anxiety, or obsessive-compulsive disorder. Every session delivers active ATTN201 stimulation; there is no sham or placebo condition. Participants and the on-site study staff who deliver stimulation and administer the clinical scales are blinded to the brain target and to the stimulation parameters assigned for each session by a constrained Bayesian optimization algorithm.

Read the detailed description

Following a remote pre-screen and an in-person screening/baseline visit (Visit 0), at which informed consent is obtained, eligibility is confirmed, baseline clinical scales are administered, optional biospecimens are collected from participants who consent to them, a multi-sequence brain MRI is acquired for targeting, and monitoring devices are fitted, each participant receives between 3 and 10 ATTN201 stimulation sessions spaced approximately 7 days apart. Each stimulation visit serves as the pre-stimulation baseline for that session, the 1-week post-stimulation measurement for the prior session, and the 2-week post-stimulation measurement for the session before that. A platform-administered scale battery at day 7 after the last stimulation captures the 1-week measurement for the final session; a remote final treatment-period follow-up approximately 2 weeks after the last stimulation captures the 2-week measurement. A remote 3-month post-treatment check-in captures durability and any delayed adverse events.

The trial uses a two-stage architecture. In Stage 1, visits are allocated across all seven candidate targets. After approximately 300 visits, the Sponsor and ARPA-H convene a joint review and select 3-5 targets for continued Bayesian optimization in Stage 2.

Monitoring during enrollment includes validated clinical scales (PHQ-9, GAD-7, OCI-R) at baseline, before each stimulation visit, at the final treatment-period follow-up, and at the 3-month follow-up; transdiagnostic visual analog scales, a morning sleep diary, and brief voice recordings prompted through the Attune platform during monitoring blocks; optional nightly ambulatory EEG; and a smart watch worn from Visit 0 through device return. All scheduled platform prompts are voluntary at the individual-prompt level.

Blinding: A single on-site research associate positions the device, runs the stimulation session, and administers participant-facing assessments, and is blinded to the brain target and parameter combination; this individual occupies both the care provider and the outcomes assessor role. The stimulation condition is selected by the Bayesian optimization algorithm and pushed to the device as a sealed session. The Lead Principal Investigator and the optimization team are unblinded as required to operate the adaptive design and do not deliver stimulation or administer participant-facing assessments. The independent Medical Monitors and the Data Safety and Monitoring Board receive unblinded safety data.

03

Conditions studied

  • Depression
  • Anxiety
  • Obsessive Compulsive Disorder (OCD)
04

Who can participate

Ages eligible
22 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be between 22 and 80 years of age (inclusive) on the day of signing .
  • Have at least one of the following at screening: PHQ-9 total score 5-16 (depression), GAD-7 total score 5-14 (anxiety), or OCI-R total score 14-27 (obsessive-compulsive disorder).
  • If currently taking psychiatric medication, have been on the same stable dose(s) for at least 4 weeks prior to screening and be willing to maintain the regimen throughout the treatment period.
  • Be able and willing to undergo a multi-sequence cranial MRI.
  • Be willing to use the ATTN201 device during stimulation visits and to attempt use of monitoring devices (optional ambulatory EEG system, smart watch) during the pre- and post-stimulation monitoring blocks; use of the optional ambulatory EEG system does not affect eligibility.
  • Sign the informed consent form, in accordance with local requirements, after the scope and nature of the investigation have been explained to the participant, and before any screening assessments.
  • Be able to speak, read, and understand English.
  • Be able to use a smartphone and the Attune platform.
  • Possess the ability to respond verbally to questions, follow instructions, and complete study assessments.
  • Be able to adhere to the treatment protocol and visit schedules through the 3-month post-treatment follow-up.
  • Be judged by the investigator as likely to comply with study procedures and willing to participate in the entirety of the study.
  • Be determined by the investigator to be medically stable at baseline as assessed by medical history and non-significant clinical results of a vital signs examination.
  • Male participants must ensure a condom is used for all sexual intercourse and follow acceptable methods of for their female partner for the entire duration of the study and for 90 days after the final study visit. Male participants should not father a child or donate sperm during this same period.
  • Female participants who are sexually active agree to use two methods of contraception for the duration of the study and for 30 days after the final study visit, or not be of as indicated by natural menopause (≥12 consecutive months of spontaneous amenorrhea), hysterectomy, bilateral tubal ligation, bilateral oophorectomy (with or without hysterectomy) more than 6 weeks prior to screening, or a vasectomized partner with documented absence of sperm.

Exclusion criteria

Exclusion Criteria:

  • Columbia Suicide Severity Rating Scale (C-SSRS) score ≥ 3 (ideation with intent, with or without plan) at screening.
  • Any suicide attempt within the past 12 months.
  • Any change in psychiatric medication (start, stop, or dose change) within 4 weeks prior to screening.
  • Has an unstable or severe medical or psychiatric condition that, in the investigator's judgment, would pose a safety risk to the participant or prevent completion of study procedures. Stable comorbid conditions (e.g., treated depression, anxiety, OCD, insomnia) within the protocol-specified score windows are permitted.
  • Has an active, unstable substance use disorder including alcohol use disorder in the past 6 months (except for caffeine and nicotine). Participants on stable medication-assisted treatment (e.g., buprenorphine, methadone, naltrexone) for at least 6 months are eligible.
  • Has a history of moderate-to-severe traumatic brain injury, or mild traumatic brain injury within the past 12 months.
  • Has a history of seizure disorder or epilepsy, or any structural CNS lesion known to lower seizure threshold.
  • Has any for completing a brain MRI scan (e.g., pacemaker, ferromagnetic implants).
  • (BMI) greater than 40 kg/m².
  • Is pregnant, is attempting to become pregnant, or is nursing.
  • Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is an site or Sponsor staff member directly involved with this trial.
  • Has a known allergy or sensitivity to ultrasound gel, silicone, or adhesive materials used in monitoring devices.
  • Has an active skin condition at sensor placement sites that would prevent device wear.
  • Has received an investigational drug or device in another clinical study within 30 days before screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Basolateral amygdala (BLA)

    ATTN201 head-worn low-intensity focused ultrasound delivered to the basolateral amygdala (BLA). Sessions at which the constrained Bayesian optimization algorithm assigns this target; stimulation parameters (pulse repetition frequency, duty cycle, target pressure) vary within the ITRUSST-bounded search space. Participants may cross over to other target arms at subsequent sessions.

    Device: ATTN201 head-worn focused ultrasound

  • Experimental
    Dorsal anterior cingulate cortex (dACC)

    ATTN201 head-worn low-intensity focused ultrasound delivered to the dorsal anterior cingulate cortex (dACC). Sessions at which the constrained Bayesian optimization algorithm assigns this target; stimulation parameters (pulse repetition frequency, duty cycle, target pressure) vary within the ITRUSST-bounded search space. Participants may cross over to other target arms at subsequent sessions.

    Device: ATTN201 head-worn focused ultrasound

  • Experimental
    Anterior limb of internal capsule (ALIC)

    ATTN201 head-worn low-intensity focused ultrasound delivered to the anterior limb of the internal capsule (ALIC). Sessions at which the constrained Bayesian optimization algorithm assigns this target; stimulation parameters (pulse repetition frequency, duty cycle, target pressure) vary within the ITRUSST-bounded search space. Participants may cross over to other target arms at subsequent sessions.

    Device: ATTN201 head-worn focused ultrasound

  • Experimental
    Centromedian nucleus of thalamus (CMN)

    ATTN201 head-worn low-intensity focused ultrasound delivered to the centromedian nucleus of the thalamus (CMN). Sessions at which the constrained Bayesian optimization algorithm assigns this target; stimulation parameters (pulse repetition frequency, duty cycle, target pressure) vary within the ITRUSST-bounded search space. Participants may cross over to other target arms at subsequent sessions.

    Device: ATTN201 head-worn focused ultrasound

  • Experimental
    Rostral zona incerta (rZi)

    ATTN201 head-worn low-intensity focused ultrasound delivered to the rostral zona incerta (rZi). Sessions at which the constrained Bayesian optimization algorithm assigns this target; stimulation parameters (pulse repetition frequency, duty cycle, target pressure) vary within the ITRUSST-bounded search space. Participants may cross over to other target arms at subsequent sessions.

    Device: ATTN201 head-worn focused ultrasound

  • Experimental
    Subthalamic nucleus (STN)

    ATTN201 head-worn low-intensity focused ultrasound delivered to the subthalamic nucleus (STN). Sessions at which the constrained Bayesian optimization algorithm assigns this target; stimulation parameters (pulse repetition frequency, duty cycle, target pressure) vary within the ITRUSST-bounded search space. Participants may cross over to other target arms at subsequent sessions.

    Device: ATTN201 head-worn focused ultrasound

  • Experimental
    Anterior nucleus of thalamus (ANT)

    ATTN201 head-worn low-intensity focused ultrasound delivered to the anterior nucleus of the thalamus (ANT). Sessions at which the constrained Bayesian optimization algorithm assigns this target; stimulation parameters (pulse repetition frequency, duty cycle, target pressure) vary within the ITRUSST-bounded search space. Participants may cross over to other target arms at subsequent sessions.

    Device: ATTN201 head-worn focused ultrasound

Interventions

  • DeviceATTN201 head-worn focused ultrasound

    ATTN201 head-worn focused ultrasound

06

What researchers measure

Primary outcomes

  1. Patient-specific transdiagnostic score (TDx) at 1 week after stimulation

    TDx measured 1 week after each stimulation session. The TDx is a severity-weighted composite of normalized improvement on PHQ-9, GAD-7, and OCI-R; higher TDx indicates greater improvement.

    Time frame: 1 week after each stimulation session

Secondary outcomes

  1. Patient-specific transdiagnostic score (TDx) at 2 weeks after stimulation

    TDx measured 2 weeks after each stimulation session. The TDx is a severity-weighted composite of normalized improvement on PHQ-9, GAD-7, and OCI-R; higher TDx indicates greater improvement.

    Time frame: 2 weeks after each stimulation session

  2. Posterior mean transdiagnostic score (TDx) at the best stimulation parameter set for each brain target

    Posterior mean TDx, from a Gaussian process model fit for each brain target, at the stimulation parameter set that maximizes it. TDx is a severity-weighted composite of normalized improvement on PHQ-9, GAD-7, and OCI-R; higher TDx indicates greater improvement.

    Time frame: At study completion, up to 19 months

  3. Change from pre-stimulation baseline in PHQ-9 total score

    Change from the local pre-stimulation baseline in Patient Health Questionnaire-9 (PHQ-9) total score. The PHQ-9 is a 9-item self-report measure of depression severity over the preceding 2 weeks. Total score range is 0 to 27; higher scores indicate greater depression severity. A negative change score indicates improvement.

    Time frame: Pre-stimulation baseline, 1 week after stimulation, and 2 weeks after stimulation

  4. Change from pre-stimulation baseline in GAD-7 total score

    Change from the local pre-stimulation baseline in Generalized Anxiety Disorder-7 (GAD-7) total score. The GAD-7 is a 7-item self-report measure of anxiety severity over the preceding 2 weeks. Total score range is 0 to 21; higher scores indicate greater anxiety severity. A negative change score indicates improvement.

    Time frame: Pre-stimulation baseline, 1 week after stimulation, and 2 weeks after stimulation

  5. Change from pre-stimulation baseline in OCI-R total score

    Change from the local pre-stimulation baseline in Obsessive-Compulsive Inventory-Revised (OCI-R) total score. The OCI-R is an 18-item self-report measure of distress associated with obsessive-compulsive symptoms. Total score range is 0 to 72; higher scores indicate greater symptom severity. A negative change score indicates improvement.

    Time frame: Pre-stimulation baseline, 1 week after stimulation, and 2 weeks after stimulation

  6. Mood visual analog scale (VAS) score

    Self-rated mood on a 0-100 continuous VAS administered through the Attune platform; higher scores indicate better mood.

    Time frame: Daily from Day 1 through Day 7 after each stimulation session

  7. Arousal visual analog scale (VAS) score

    Self-rated arousal on a 0-100 continuous VAS administered through the Attune platform; higher scores indicate greater arousal.

    Time frame: Daily from Day 1 through Day 7 after each stimulation session

  8. Sleepiness visual analog scale (VAS) score

    Self-rated sleepiness on a 0-100 continuous VAS administered through the Attune platform; higher scores indicate greater sleepiness.

    Time frame: Daily from Day 1 through Day 7 after each stimulation session

  9. Anxiety symptom visual analog scale (VAS) score

    Self-rated current anxiety symptoms on a 0-100 continuous VAS administered through the Attune platform; higher scores indicate greater anxiety.

    Time frame: Daily from Day 1 through Day 7 after each stimulation session

  10. Obsessive-compulsive symptom visual analog scale (VAS) score

    Self-rated current obsessive-compulsive symptoms on a 0-100 continuous VAS administered through the Attune platform; higher scores indicate greater symptom severity.

    Time frame: Daily from Day 1 through Day 7 after each stimulation session

  11. Depression symptom visual analog scale (VAS) score

    Self-rated current depression symptoms on a 0-100 continuous VAS administered through the Attune platform; higher scores indicate greater symptom severity.

    Time frame: Daily from Day 1 through Day 7 after each stimulation session

  12. Prefrontal EEG delta band spectral power

    Absolute spectral power in the delta band from nightly two-channel prefrontal ambulatory EEG recordings, among participants who elect optional EEG monitoring.

    Time frame: Nightly from Day 1 through Day 7 after each stimulation session

  13. Prefrontal EEG theta band spectral power

    Absolute spectral power in the theta band from nightly two-channel prefrontal ambulatory EEG recordings, among participants who elect optional EEG monitoring.

    Time frame: Nightly from Day 1 through Day 7 after each stimulation session

  14. Prefrontal EEG alpha band spectral power

    Absolute spectral power in the alpha band from nightly two-channel prefrontal ambulatory EEG recordings, among participants who elect optional EEG monitoring.

    Time frame: Nightly from Day 1 through Day 7 after each stimulation session

  15. Prefrontal EEG beta band spectral power

    Absolute spectral power in the beta band from nightly two-channel prefrontal ambulatory EEG recordings, among participants who elect optional EEG monitoring.

    Time frame: Nightly from Day 1 through Day 7 after each stimulation session

  16. Prefrontal EEG gamma band spectral power

    Absolute spectral power in the gamma band from nightly two-channel prefrontal ambulatory EEG recordings, among participants who elect optional EEG monitoring.

    Time frame: Nightly from Day 1 through Day 7 after each stimulation session

  17. EEG-derived sleep efficiency

    Sleep efficiency (percentage of time in bed spent asleep) derived by automated sleep staging of nightly two-channel prefrontal ambulatory EEG recordings, among participants who elect optional EEG monitoring.

    Time frame: Nightly from Day 1 through Day 7 after each stimulation session

  18. Smart-watch-derived heart rate variability

    Daily heart rate variability (milliseconds) recorded by the study smart watch.

    Time frame: Daily from Day 1 through Day 7 after each stimulation session

  19. Smart-watch-derived daily step count

    Daily step count (actigraphy) recorded by the study smart watch.

    Time frame: Daily from Day 1 through Day 7 after each stimulation session

  20. Smart-watch-derived sleep duration

    Nightly total sleep duration (minutes) recorded by the study smart watch.

    Time frame: Nightly from Day 1 through Day 7 after each stimulation session

  21. Life-space mobility

    Daily life-space mobility (maximum distance from home, kilometers) derived from de-identified GPS collected by the optional Beiwe research application on the participant's smartphone.

    Time frame: Daily from Day 1 through Day 7 after each stimulation session

  22. Patient-specific transdiagnostic score (TDx) at 1 week after stimulation, by primary indication

    TDx measured 1 week after each stimulation session, summarized separately for participants whose primary indication is depression, anxiety, obsessive-compulsive disorder, or comorbid. TDx is a severity-weighted composite of normalized improvement on PHQ-9, GAD-7, and OCI-R; higher TDx indicates greater improvement.

    Time frame: 1 week after each stimulation session

07

Study locations

1 of 2 sites recruiting
  • Attune Neurosciences, Inc.
    San Francisco, California 94107, United States
    Not yet recruiting
  • Attune, San Francisco Clinical Research Center
    San Francisco, California 94107, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data will be deposited into the ARPA-H designated data repository as required by the funded ARPA-H EVIDENT program. Deposited data include clinical outcome measures (PHQ-9, GAD-7, OCI-R, PROMIS Sleep Disturbance 8a, PROMIS Sleep-Related Impairment 8a, DASS-8, Brief Resilience Scale, Flourishing Scale, and transdiagnostic visual analog scales), delivered stimulation parameters, EEG-derived and wearable-derived biomarker measures, platform-derived measures, relevant metadata, and optional baseline dried blood spot and saliva biospecimens where collected. Participant identifiers are not included in deposited datasets.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Deposits occur on rolling quarterly delivery cycles beginning after enrollment of the first participant and continuing through study completion. Deposited data remain available thereafter under the retention terms of the ARPA-H designated data repository.

Access criteria: Access is governed by the data access procedures of the ARPA-H designated data repository. Requests for deposited data are made to the repository rather than to the sponsor.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2028, 17 months after the start.

Of 98 industry-sponsored interventional studies with no phase under Depression, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 17 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2026
First posted
Oct 1, 2026
StartActual
Oct 19, 2026
Primary completionEst.
Apr 5, 2028
CompletionEst.
May 17, 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
1 site added. Attune Neurosciences, Inc. is now Not yet recruiting
Show site
  • Attune, San Francisco Clinical Research Center · San Francisco, United States
Oct 27, 2026
Start date
Oct 5, 2026→Oct 19, 2026 (actual)
Oct 27, 2026
Contact
Study contact's phone or email changed: k•••@attuneneuro.com→o•••@attuneneuro.com. See the current contact
Oct 27, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Oct 27, 2026
    Not yet recruiting→Recruiting
    1 site added. Attune Neurosciences, Inc. is now Not yet recruiting
    Show site
    • Attune, San Francisco Clinical Research Center · San Francisco, United States
    Start date Oct 5, 2026→Oct 19, 2026 (now actual)
    Contact Study contact's phone or email changed: k•••@attuneneuro.com→o•••@attuneneuro.com. See the current contact
    + 1 other change: verification date
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851038
Lead sponsor
Attune Neurosciences Inc
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Oct 19, 2026
Primary completion
Apr 5, 2028 (estimated)
Completion
May 17, 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Keith Murphy, PhD
Contact
outreach@attuneneuro.com
415-658-7001

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion